Lymphoma treatment is focusing increasingly on novel agents with specific targets. At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Laurie Sehn, MD, of the University of British Columbia, Vancouver, Canada, chaired a panel discussion on novel targets and agents in lymphoma. Targets discussed included Syk-JAK, BTK, MCL-1, BCL2, and XPO1. Demethylating agents, polatuzumab combinations, umbralisib combinations, and the optimal therapies for double-and triple-hit diffuse large B-cell lymphoma were also explored. The speakers in this discussion were John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, and Kieron Dunleavy, MD, from George Washington University, Washington, DC.
Novel targets and agents for lymphoma
